Selecting the optimal oral antihistamine for patients with allergic rhinitis

Drugs

Volumn 66, Issue 18, 2006, Pages 2309-2319

  Lehman, Jeffrey M ^a   Blaiss, Michael S ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; DESLORATADINE; DIPHENHYDRAMINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; PLACEBO; RIFAMPICIN; TERFENADINE;

ALERTNESS; ALLERGIC RHINITIS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIAGNOSTIC ERROR; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG PENETRATION; DYSMENORRHEA; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HEADACHE; HUMAN; NASAL PRURITUS; NOSE CONGESTION; PATHOPHYSIOLOGY; PERFORMANCE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOMOTOR ACTIVITY; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; SOMNOLENCE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

ACARI; ANIMALIA; BLATTARIA;

EID: 33846042017     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00004     Document Type: Review

References (117)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5): 478-518
2. Gandhi RK, Blaiss MS. Current concepts and therapeutic strategies for allergic rhinitis. Otorinolaringol 2005; 55 (3): 187-201
3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001 Jul; 108 (1): S2-8
4. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006 Jan; 117 (1): 158-62
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 Nov; 108 Suppl. 5: S147-334
6. Leynaert B, Neukirch C, Laird R, et al. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med 2000 Oct; 162 (4): 1391-6
7. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 2004 Nov; 114 (5): S139-45
8. Huse DM, Hartz SE, Russell MW, et al. Allergic rhinitis may worsen asthma symptoms in children: the international asthma outcomes registry [abstract]. Am J Respir Crit Care Med 1996; 153: A860
9. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89: 611-8
10. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781-6
11. Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004; 26 (11): 1876-89
12. Naclerio RM. Allergic rhinitis. N Engl J Med 1991 Sep; 325 (12): 860-9
13. Meltzer EO. Evaluation of the optimal oral antihistamine for patients with allergic rhinitis. Mayo Clin Proc 2005 Sep; 80 (9): 1170-6
14. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985 Jul; 313 (2): 65-70
15. Bascom R, Pipkorn U, Lichtenstein LM, et al. The influx of inflammatory cells into nasal washings during the late response to antigen challenge: effect of systemic steroid pretreatment. Am Rev Respir Dis 1988; 138: 406-12
16. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427-39
17. 1- receptor-antagonist drugs. N Engl J Med 1994; 330: 1663-70
18. 1 receptor [abstract no. 526]. J Allergy Clin Immunol 2001; 107 Suppl. 2: 160
19. 1 receptor. Eur J Pharmacol 2002; 449: 229-37
20. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987; 59 (6 Pt 2): 4-8
21. 1 receptor. J Biol Chem 1999; 274: 29994-30000
22. 1-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-42
23. 1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-98
24. 1-antagonists. Clin Exp Allergy 1990 Aug; 20 Suppl. 2: 3-17
25. Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg 1993 Jun; 108 (6): 723-30
26. 1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 1999; 29 Suppl. 3: 49-53
27. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369-77
28. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000 Jun; 105 (6): S622-7
29. van Cauwenberge P, Bachert C, Passalacqua G, et al. European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116-34
30. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. Allergy 1994; 49 Suppl. 19: 1-34
31. 1-receptor antagonists: an EAACI position paper. Allergy 1996 Oct; 51 (10): 666-75
32. 1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329-52
33. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15: 269-77
34. 1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997; 79: 530-2
35. 1-antihistamines. N Engl J Med 2004 Nov; 351 (21): 2203-17
36. Hindmarch I, Johnson S, Meadows R, et al. The acute and subchronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17: 241-55
37. 1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002 Apr; 57: 346-50
38. Geha RS, Meltzer EO. Desloratadine: a new nonsedating, oral antihistamine. J Allergy Clin Immunol 2001 Apr; 107: 751-62
39. 1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526-30
40. Passalacqua G, Canonica GW. A review of evidence from comparative studies of levocetirizine and desloratadine for symptoms of allergic rhinitis. Clin Ther 2005 Jul; 27 (7): 979-92
41. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 3): S307-18
42. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341-84
43. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 449-54
44. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Units (EEU). Int J Clin Pract 2004; 59: 109-18
45. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 617-6
46. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 507-11
47. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160-6
48. Pearlman DS, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr 1997; 36: 209-15
49. Sabbah A, Daele J, Wade AG, et al. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1999; 83: 319-25
50. Murray JJ, Nathan RA, Bronsky EA, et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 391-8
51. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003; 33: 351-8
52. Horak F, Stübner UP, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg od and fexofenadine 120mg od in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73-9
53. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-33
54. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354-61
55. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Asthma Allergy Immunol 1997; 79: 163-72
56. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638-45
57. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077-80
58. Salmun LM, Lorber R, Danzig M, et al. Efficacy and safety of desloratadine in seasonal allergic rhinitis [abstract no. 1123]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 384-5
59. Heithoff K, Meltzer EO, Mellars L, et al. Desloratadine improves quality of life in patients with seasonal allergic rhinitis [abstract no. 1121]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 383-4
60. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21: 25-32
61. Berger WE, Schenkel EJ, Mansfield LE, et al. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89: 485-91
62. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Pract 2002; 3: 14-20
63. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 1504-9
64. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533-40
65. Wahn U, Meltzer EO, Finn AF, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 111: 763-9
66. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 100-6
67. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergy rhinitis. Allergy Asthma Proc 1999; 20: 193-8
68. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135-41
69. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311-7
70. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443-8
71. van Cauwenberge P, Juniper EF, Meltzer EO, et al. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891-9
72. Mösges R, van Cauwenberg P, Purello-D'Ambrosio F, et al. Fexofenadine and loratadine exhibit rapid relief, but only fexofenadine maintains efficacy over a 2-week period [abstract no. 1005]. Allergy 2000; 55 Suppl. 63: 281
73. Ricard N, Kind P, Christian S, et al. Link between preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation. Clin Ther 1999; 20: 268-77
74. Serra HA, Alves O, Rizzo LFL, et al. Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial. Br J Clin Pharmacol 1998; 45: 147-50
75. Druce HM, Thoden WR, Mure P, et al. Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative trial. J Clin Pharmacol 1998; 38: 382-9
76. 1-receptor antagonist. J Med Chem 1998; 41: 853-63
77. Best CH, Dale HH, Dudley HW, et al. The nature of the vasodilator constituents of certain tissue extracts. J Physiol 1927; 62: 397-417
78. Zyrtec® (cetirizine hydrochloride) tablets and syrup: package insert. New York: Pfizer Inc., 2002
79. Mohler SR, Nicholson A, Harvey RP, et al. The use of antihistamines in safety-critical jobs: a meeting report. Curr Med Res Opin 2002; 18: 332-7
80. Lai DS, Lue KH, Hsieh JC, et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 589-98
81. Burtin B, Duchateau J, Pignat JC, et al. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. Invest Allergol Clin Immunol 2000; 10: 66-70
82. Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003 Oct; 112 (4 Suppl.): S78-82
83. Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 1997; 157: 2350-6
84. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999; 29 Suppl. 3: 133-42
85. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005; 65 (2): 215-28
86. Paolieri F, Battifora M, Riccio A, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81: 601-7
87. Allegra® (fexofenadine hydrochloride) capsules and tablets: package insert. Kansas City (MO): Aventis Pharmaceuticals Inc., 2003
88. Clarinex® (desloratadine) tablets: package insert. Kenilworth (NJ): Schering Corporation, 2002
89. Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003; 74: 145-52
90. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187
91. Simons FER, Prenner BM, Finn A. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003; 111: 617-22
92. Xyzal® (levocetirizine) tablets: package insert. Brussels: UCB Pharma Ltd, 2003
93. deBlic J, Wahn U, Billard E. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005 May; 16 (3): 267-75
94. Lee DK, Gardiner M, Haggart K, et al. Comaprative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650-3
95. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52-6
96. Bockholdt B, Klug E, Schneider V. Suicide through doxylamine poisoning. Forensic Sci Int 2001; 119: 138-40
97. Baker AM, Johnson DG, Levisky JA, et al. Fatal diphenhydramine intoxication in infants. J Forensic Sci 2003; 48: 425-8
98. Claritin® (loratadine) tablets, syrup, and rapidly-disintegrating tablets: package insert. Kenilworth (NJ): Schering Corporation, 2000
99. Timmerman H. Factors involved in the absence of sedative effects by second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 5-10
100. Simons FER, Fraser TG, Maher J, et al. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999; 82: 157-60
101. Simons FER, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092-7
102. Scharf MB, Kay G, Rikken G, et al. Desloratadine has no effect on wakefulness or psychomotor performance [abstract no. 1001]. Allergy 2000; 55 Suppl. 63: 280
103. 1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890-900
104. Ramaekers JG, Uiterwijk MMC, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363-9
105. Vermeeren A, Ramaekers JG, O'Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002; 16: 57-64
106. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64: 520-6
107. Gengo FM, Gabos C. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987; 59 (6 Pt 2): 53-7
108. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992; 69: 195-200
109. Vuurman EFPM, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004; 60: 307-13
110. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo- controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200-6
111. Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003 Mar; 111 (3): 623-7
112. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52-6
113. Milne RW, Larson LA, Jorgensen KL, et al. Hepatic disposition of fexofenadine: influence of the inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000; 17: 1511-5
114. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98
115. Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802-9
116. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11-20
117. Hamman MA, Bruce MA, Hachner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114-21